|
tbar.gif
Click
here to
submit entries
|
|
|
Osmetech
Cheers Warfarin Study |
February
12, 2008--The Marshfield Clinic Research Foundation published an
article demonstrating that the warfarin biomarker, 4F2, will help reduce
adverse reactions to the drug. If a warfarin dose is too high or too low,
there is a risk of serious bleeding or clotting events. James White, CEO
of Osmetech, said in a statement: “The fact that Osmetech has an
exclusive license to this marker for warfarin testing, we believe will
help position us as the leading diagnostic company in this area.” Osmetech
|
|
|
Genstruct: Patience, Persistence, and Payoff
By John Russell |
|
Finding the right business model for systems biology (SB) technology providers has been challenging — that’s hardly a new theme in biotech.
Click
here
|
|
|
